Moderna (MRNA) Earnings: 2025 Revenue Forecast Slashed Below Estimates

Moderna on Smartkarma

Analysts at Baptista Research are bullish on Moderna Inc., a biotechnology company revolutionizing the global healthcare landscape. In their report titled “Moderna Inc.: Expanding Global Presence For Unmatched Impact! – Major Drivers,” they highlighted the company’s strong financial performance in the third quarter of 2024. With $1.9 billion in revenue and a net income of $13 million, Moderna ended the quarter with $9.2 billion in cash and investments, showcasing robust liquidity for future growth and innovation.

Furthermore, in another report by Baptista Research titled “Moderna Inc.: These Are The 4 Biggest Challenges That Bears Are Counting On! – Major Drivers,” the analysts emphasized the positive developments in Moderna’s respiratory vaccine portfolio. Particularly, the success of mRNA-1273, Moderna’s COVID-19 vaccine, and the new RSV vaccine, mRESVIA, have been significant drivers of growth. With mRNA-1273 playing a vital role in combating COVID-19 and showing promising results, Moderna continues to stand out in the biopharmaceutical sector.

A look at Moderna Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Moderna, Inc., a biotechnology company specializing in messenger RNA therapeutics and vaccines, has been given a promising outlook according to Smartkarma Smart Scores. With high scores in Value and Resilience, Moderna is positioned well for long-term success. The company’s focus on developing mRNA medicines for various diseases shows potential for growth despite lower scores in Dividend and Momentum.

Looking ahead, Moderna’s strong foundation in technology and research in the biotechnology sector gives confidence in its ability to innovate and adapt to market demands. While the company may have room to improve in areas like Growth and Momentum, its solid performance in Value and Resilience suggests a positive outlook for investors seeking a stable and potentially lucrative venture in the biotech industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma